NCT07416188 2026-03-18
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Not yet recruiting
Clinical Trials
14 trialsNCT07437963 2026-03-18
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
NCT06639607 2026-03-10
PRiME II
Washington University School of Medicine
Phase 1/2 Not yet recruiting
NCT07346144 2026-03-04
ADePT
Trogenix ltd
Phase 1/2 Not yet recruiting
NCT07431216 2026-02-24
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
Lantern Pharma Inc.
Phase 1/2 Not yet recruiting
NCT07392957 2026-02-06
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
Washington University School of Medicine
Phase 1/2 Not yet recruiting
NCT07131722 2026-01-23
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II
PRG Science & Technology Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07346157 2026-01-16
PNOC044
University of California, San Francisco
Phase 1/2 Not yet recruiting
NCT04373785 2025-10-21
NG101m Adjuvant Therapy in Glioblastoma Patients
NeuGATE Theranostics
Phase 1/2 Not yet recruiting
NCT07177950 2025-09-17
A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases
Peking University Cancer Hospital & Institute
Phase 1/2 Not yet recruiting
NCT06735820 2025-07-03
MEKMDM2
Children's National Research Institute
Phase 1/2 Not yet recruiting
NCT07024394 2025-06-17
Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1/2 Not yet recruiting
NCT06258018 2024-08-30
ONC-2022-001
Istituto Clinico Humanitas
Phase 1/2 Not yet recruiting
NCT06329570 2024-03-26
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
Phase 1/2 Not yet recruiting